vinpocetine has been researched along with Disease Exacerbation in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hsu, CG; Li, D; Mohan, A; Shi, H; Yan, C; Zhang, C | 1 |
| Fan, F; Li, H; Li, S; Lu, Y; Peng, W; Wang, K; Xu, Y; Zhuang, J | 1 |
| Chukanova, EI | 1 |
| Cuşnir, R; Cuşnir, V; Dumbravă, V; Midrigan, I; Slepova, O; Zaiţeva, N | 1 |
1 trial(s) available for vinpocetine and Disease Exacerbation
| Article | Year |
|---|---|
[Cavinton in the complex treatment of patients with chronic cerebrovascular insufficiency].
Topics: Aged; Aged, 80 and over; Blood Pressure; Calcium Channel Blockers; Cerebrovascular Disorders; Cognition; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Motor Activity; Treatment Outcome; Vinca Alkaloids | 2009 |
3 other study(ies) available for vinpocetine and Disease Exacerbation
| Article | Year |
|---|---|
Vinpocetine protects against the development of experimental abdominal aortic aneurysms.
Topics: Animals; Aortic Aneurysm, Abdominal; Cells, Cultured; Dilatation, Pathologic; Disease Progression; Elastin; Inflammation; Macrophages; Mice, Inbred C57BL; Myocytes, Smooth Muscle; NF-kappa B; Protective Agents; Proteoglycans; Proteolysis; Vinca Alkaloids | 2020 |
Inhibitory effects of vinpocetine on the progression of atherosclerosis are mediated by Akt/NF-κB dependent mechanisms in apoE-/- mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cyclic Nucleotide Phosphodiesterases, Type 1; Disease Models, Animal; Disease Progression; Foam Cells; Humans; I-kappa B Proteins; Inflammation; Lipoproteins, LDL; Male; Mice; Mice, Knockout; Monocytes; NF-kappa B; Oxidative Stress; Phosphorylation; Plaque, Atherosclerotic; Proto-Oncogene Proteins c-akt; Signal Transduction; Vinca Alkaloids | 2013 |
[Ocular manifestations of hepatitis B].
Topics: Adolescent; Adult; Case-Control Studies; Cataract; Conjunctiva; Disease Progression; Eye Diseases; Female; Hepatitis B; Humans; Limbic System; Male; Middle Aged; Treatment Outcome; Vasodilator Agents; Vinca Alkaloids | 1997 |